Updates in the Pipeline of HIV Therapy

Infectious Disease Special Edition | January 14, 2022

NIH celebrates FDA approval of long-acting injectable drug for HIV prevention

NIH | December 21, 2021

FDA Approves APRETUDE (cabotegravir) for HIV-1 Pre-Exposure Prophylaxis

FDA | December 20, 2021

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV

At Last, Generic HIV Prevention Drugs Promise Savings And Access—But Also Reveal Precarious Financing

Health Affairs | May 20, 2021

Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

Novel Antiretroviral Agents

Current HIV/AIDS Reports Feb 2020

IAS Panel Releases Updated 2020 Guidelines on ART and HIV Prevention 

Infectious Disease Advisor | December 4, 2020

Changes in drug interaction profiles for first-line HIV therapy over the 20 years of the Liverpool Drug Interaction website

Department of Pharmacology & Therapeutics, University of Liverpool

Proportion of serious drug interactions dropping on Liverpool antiretroviral website

20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands

HIV Provider Organization to Launch New Web Resource on Long-Acting Agents

American Academy of HIV Medicine | January 6, 2022

Dolutegravir-Based Treatment More Effective in Children Living With HIV

Contagion Live | January 6, 2022

Outcomes of Dolutegravir Treatment in Patients With HIV Infection Who Failed Antiretroviral Therapy 

Infectious Disease Advisor | January 5, 2022

HIV Drug Resistance Report - November 2021

ReliefWeb | November 24, 2021

Injectable HIV treatment for patients in UK | HIV AIDS | Health News 

YouTube | November 22, 2021

Clinics will need new systems to administer injectable HIV therapies, says Canadian early adopter 

Aidsmap | November 5, 2021

Ibrutinib improves survival for younger people with diffuse large B-cell lymphoma

NIH | November 4, 2021

Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults

NATAP | October 26, 2021

Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression: pOLAR month 12 results 

AIDS. 2021 Oct 13. doi: 10.1097/QAD.0000000000003085.

ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals

ViiV | 28 September 2021

The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis

Antivir Ther. 2020;25(1):21-32. doi: 10.3851/IMP3346

FDA Approves Pfizer Booster Shots for Seniors, High-Risk Americans

Agents Used in Antiretroviral Therapy

Clinical Care Options | September 2021

Researchers advance the use of nanoparticles to deliver HIV/AIDS drugs to the brain

FIU News | September 17, 2021

First-in-Class NRTTI Demonstrates Potential as Long-Acting Oral PrEP Against HIV

Contagionlive.com | September 10, 2021

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study

Open Forum Infect Dis. 2021 Aug 25;8(9):ofab439. doi: 10.1093/ofid/ofab439. eCollection 2021 Sep.

Direct oral anticoagulants versus warfarin in people living with human immunodeficiency virus 

Int J STD AIDS. 2021 Jul 23;9564624211031728. doi: 10.1177/09564624211031728

Changes to the Epclusa product label for use in pediatrics

FDA | June 2021

Changes to the Mavyret product labeling for use in pediatrics

FDA | June 2021

How modern medication has extended the life span of people with HIV over the past 40 years 

California News Times | May 2021

Six drugmakers are in violation of 340B statute, says HRSA 

Healthcare Finance News | May 18, 2021

Clinical Insights into New Treatment Options for HIV: Cabenuva and Vocabria 

Pharmacy Times | May 10, 2021

ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV

Business Wire | May 4, 2021